Functional Medicine for Long COVID 2026: Evidence-Based Protocol Guide

Last updated: April 2026

Medical Disclaimer: This article is for educational purposes only. It is not medical advice and does not replace the care of a licensed clinician. Long COVID is a complex, multi-system condition. Talk to your doctor before starting any supplement, prescription, or lifestyle protocol — especially if you take blood thinners, immunosuppressants, or opioids (low-dose naltrexone interacts with opioid medications). Some interventions discussed here are off-label or investigational.

Affiliate Disclosure: Some links in this article are affiliate links. If you buy through them, we may earn a small commission at no extra cost to you. We only recommend products and services we'd send our own family to. Editorial coverage is never paid for.

Quick Answer: What's the functional medicine protocol for long COVID?

• Test first, treat second. A functional workup screens for microclots (D-dimer, fibrinogen), autoimmunity (ANA, thyroid, anti-cardiolipin), mast cell activation (tryptase, chromogranin A, 24-hr urinary N-methylhistamine), and mitochondrial dysfunction (organic acids, lactate). Mount Sinai's long COVID lab found elevated D-dimer in roughly 1 in 4 patients (Putrino lab, 2024).
• Stack four pillars: anti-inflammatory immune support (LDN, quercetin, omega-3), mitochondrial repair (CoQ10, NAD+, B-complex), microvascular/microclot support (nattokinase, lumbrokinase, low-dose anticoagulation when indicated), and nervous-system regulation (vagal toning, pacing, sleep).
• Pace ruthlessly. Post-exertional malaise (PEM) hits an estimated 89% of long COVID patients with ME/CFS-type presentation (Davis et al., Nature Reviews Microbiology, 2023). Pushing through worsens outcomes. Use heart-rate-based pacing.
• CDC NHIS data show 6.9% of U.S. adults reported long COVID symptoms in 2024, roughly 17.6 million people, with 26% reporting significant activity limitation (CDC NHIS, 2024).

Long COVID isn't one disease. It's at least four overlapping subtypes — viral persistence, autoimmunity, microclot/microvascular, and dysautonomia — and the treatment that works depends on which one you have. That's where functional medicine differs from a 15-minute primary care visit. The workup is broader, the protocol is layered, and progress is measured in months, not weeks.

According to a 2024 Lancet review, an estimated 65 million people worldwide live with long COVID, and only a fraction have access to multidisciplinary care (Al-Aly et al., Lancet, 2024). The RECOVER initiative — the NIH's $1.6 billion long COVID research program — is finally pivoting from observation to treatment trials in 2026, with low-dose naltrexone, IVIG, and pacing protocols all entering randomized phases (FNIH RECOVER-TLC, 2026).

This guide walks through what functional medicine practitioners are actually doing in 2026, what the evidence says, what it costs, and where the science is still soft. If you want the entity directory of clinicians who do this work, see our /practitioners listing.

What is long COVID, and what are the subtypes?

Long COVID — formally post-acute sequelae of SARS-CoV-2 infection (PASC) — is defined by the WHO as symptoms persisting at least three months after acute infection, lasting at least two months, and not explained by another diagnosis. The CDC uses a similar four-week threshold.

Researchers now describe four (sometimes five) overlapping clusters:

1. Viral persistence / reservoir. SARS-CoV-2 RNA and spike protein have been found in gut tissue, lymph nodes, and brain up to 2+ years post-infection (Swank et al., Clinical Infectious Diseases, 2023). Patients in this cluster often respond to antivirals.
2. Autoimmune. New-onset autoantibodies, including anti-ACE2, anti-G-protein-coupled receptor antibodies, and connective tissue markers. A 2024 Nature paper from Akiko Iwasaki's Yale lab found persistent immune dysregulation and elevated autoantibody burden in long COVID patients vs. matched controls (Klein et al., Nature, 2023).
3. Microclot / microvascular. Fibrinaloid microclots resist normal fibrinolysis. Resia Pretorius's lab at Stellenbosch University documented these structures repeatedly. Symptoms cluster around brain fog, exercise intolerance, and POTS.
4. Mast cell activation syndrome (MCAS). Hives, flushing, GI symptoms, food sensitivities, fragrance intolerance — a hyperactive innate immune state. Estimated to affect 17-21% of long COVID patients (Weinstock et al., International Journal of Infectious Diseases, 2021).
5. Dysautonomia / POTS. Heart rate spikes on standing, dizziness, exercise intolerance. Around 30% of long COVID patients meet POTS criteria (Vernino et al., 2022).

Most patients have features of two or three subtypes at once. That's why the protocol stacks. As Dr. David Putrino, Director of Rehabilitation Innovation at Mount Sinai Health System, put it in a 2024 STAT News interview: "This is not one disease. We're treating a syndrome with four or five mechanistic engines, and patients need different combinations of brakes and accelerators depending on which engines are running hot."

What does the science say about long COVID treatment in 2026?

Honest answer: there's still no FDA-approved long COVID drug. But the evidence base for several off-label interventions has thickened considerably in the last 18 months.

RECOVER-TLC (Treating Long COVID). The NIH's RECOVER initiative pivoted in late 2024 from natural-history studies to interventional trials. As of Q1 2026, the active or imminent trials include:

• Low-dose naltrexone (RECOVER-NEURO, expanded to pediatric/young-adult enrollment summer 2026)
• IVIG for autoimmune-pattern long COVID
• Cardiopulmonary rehab + autonomic retraining
• Lumbrokinase (microclot pathway), driven by Putrino's Mount Sinai data
• Paxlovid 15-day extended course (viral persistence pathway)

Low-dose naltrexone (LDN). A 2025 systematic review and meta-analysis in MDPI's COVID journal found LDN improved fatigue, brain fog, and pain in pooled long COVID cohorts (Tan et al., COVID, 2025). A 2024 Frontiers in Molecular Biosciences study from the Griffith University ME/CFS lab showed LDN restored TRPM3 ion channel function in natural killer cells from long COVID patients — a plausible mechanism for the symptomatic improvement (Cabanas et al., Frontiers Mol Biosci, 2025). Typical dose: 1.5-4.5mg nightly, compounded.

Nattokinase, serrapeptase, lumbrokinase. A 2024 patient survey of 668 long COVID respondents found 40-70% reported symptom relief from these enzyme thrombolytics (Putrino lab Mount Sinai, 2024). This isn't a randomized trial — it's a survey — but it's strong enough that Putrino is running a 120-person lumbrokinase RCT.

Antihistamines + mast cell stabilizers. H1 + H2 blocker combinations (e.g., loratadine + famotidine) plus low-dose ketotifen or cromolyn show consistent benefit in MCAS-pattern long COVID (Weinstock, IJID, 2021).

Coenzyme Q10, NAD+, B-vitamins. A 2024 PMC review documented persistent mitochondrial dysfunction in long COVID, with reduced ATP and elevated lactate at submaximal exertion (Guarnieri et al., 2024). Targeted mitochondrial support has the strongest mechanistic rationale, though RCT data are still thin.

What hasn't worked (or didn't survive RCTs): ivermectin (RECOVER-VITAL, 2024 — null), metformin for symptomatic long COVID (mixed; prevention signal exists), hyperbaric oxygen (small-positive trials but expensive and inconsistent at scale).

How do functional doctors test for long COVID?

A functional medicine workup typically runs $400-$1,500 out of pocket beyond standard insurance labs. Here's what's on the panel in 2026:

Microclot and microvascular markers

• D-dimer (cutoff debated; Mount Sinai uses >250 ng/mL FEU as suspicious in symptomatic patients)
• Fibrinogen
• Anti-cardiolipin antibodies (IgG, IgM)
• Anti-beta-2 glycoprotein antibodies
• vWF antigen and activity
• PT/PTT, platelet count

The gold-standard imaging — fluorescence microscopy of platelet-poor plasma to visualize fibrinaloid microclots — is largely a research test (Pretorius lab, Stellenbosch). It's not commercially available in the U.S. for clinical decision-making. D-dimer + fibrinogen + clinical pattern is the practical workup.

Autoimmune panel

• ANA with reflex titers and pattern
• TSH, free T3, free T4, TPO, thyroglobulin antibodies (post-viral thyroiditis is common — see our /functional-medicine-thyroid-issues guide)
• Rheumatoid factor, anti-CCP
• Complement C3, C4
• Anti-ACE2 antibody (research labs)

MCAS markers (timing matters — collect during a flare)

• Serum tryptase (often normal in MCAS — don't rule out on this alone)
• Chromogranin A
• 24-hour urinary N-methylhistamine
• 24-hour urinary prostaglandin D2 and 11-β-prostaglandin F2α
• 24-hour urinary leukotriene E4

Mitochondrial and metabolic

• Organic acids urine test (OAT) — flags Krebs cycle, methylation, B-vitamin status
• Lactate (resting and post-exertion)
• Carnitine, free and total
• CoQ10 level
• Vitamin D, B12, folate, ferritin
• Hemoglobin A1c, fasting insulin

Viral persistence / reactivation

• EBV panel (VCA IgG, VCA IgM, EA-D, EBNA) — reactivation is common
• HHV-6, CMV antibodies
• SARS-CoV-2 spike and nucleocapsid antibodies (qualitative)

Dysautonomia screening

• 10-minute NASA lean test (heart rate increase >30 bpm on standing = POTS criterion)
• Tilt-table testing if NASA lean is positive

For a deeper cost breakdown, see our /functional-medicine-lab-tests-typical-costs page. Many of these labs are HSA-eligible — see /how-to-use-hsa-for-functional-medicine.

Anti-inflammatory and immune support protocol

The goal here isn't immune suppression — it's immune recalibration. Long COVID patients often have a paradoxical state: chronic low-grade inflammation alongside impaired antiviral signaling.

Low-dose naltrexone (LDN). The single most-discussed off-label long COVID drug. Mechanism: opioid growth factor receptor modulation, microglial quieting, TRPM3 channel restoration in NK cells (Cabanas et al., 2025). Standard titration: 0.5mg → 1.5mg → 3mg → 4.5mg nightly over 4-8 weeks. Side effects (vivid dreams, sleep disruption) usually fade. Requires a compounding pharmacy. Typical cost: $30-$70/month.

Quercetin + bromelain. Quercetin is a mast cell stabilizer and zinc ionophore. Bromelain enhances absorption and adds mild fibrinolytic activity. Typical dose: 500-1,000mg quercetin twice daily.

Omega-3 (EPA/DHA). Aim for combined EPA+DHA of 2-4g/day from a low-oxidation, third-party-tested source. A 2023 systematic review in Nutrients found omega-3 supplementation reduced inflammatory markers in post-viral and chronic fatigue states (Mehta et al., 2023).

Curcumin (high-bioavailability). 500-1,000mg twice daily of a phytosome or liposomal form. Reduces NF-κB signaling. Avoid if on warfarin without medical supervision.

Vitamin D. Optimize to 50-80 ng/mL. Long COVID patients are disproportionately vitamin D deficient (Barrea et al., 2022). Typical dose 2,000-5,000 IU/day with K2.

Famotidine (H2 blocker) + loratadine or fexofenadine (H1 blocker). Standard MCAS sandwich. Famotidine 20-40mg twice daily plus an H1 antihistamine. Cheap, generally well-tolerated.

A note on hidden supplement costs: stacking 8-12 supplements adds up fast. Read /functional-medicine-supplements-hidden-costs before you blow $400/month on overlapping products.

Mitochondrial support protocol

Long COVID patients show measurable mitochondrial dysfunction — reduced ATP synthesis, abnormal lactate kinetics, and impaired fatty-acid oxidation. A 2024 study in Nature Communications documented skeletal muscle mitochondrial damage that persisted at 6-month follow-up post-infection (Appelman et al., Nature Communications, 2024).

The mitochondrial protocol typically includes:

CoQ10 (ubiquinol form). 200-400mg/day with fat. Direct electron transport chain support. A 2023 randomized trial showed CoQ10 + alpha-lipoic acid improved fatigue scores in post-COVID patients (Barletta et al., 2023).

NAD+ precursors. Nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), 250-500mg/day. NAD+ levels drop in long COVID. A small open-label trial of LDN + NAD+ infusions showed improvement in patient-reported fatigue (PMC10862402, 2024).

Acetyl-L-carnitine. 1,000-2,000mg/day. Supports fatty-acid transport into mitochondria.

B-complex (methylated). Methylfolate, methylcobalamin, P5P (B6), riboflavin-5-phosphate. Many long COVID patients have functional B-vitamin insufficiency on organic acids testing.

Magnesium glycinate or malate. 200-400mg elemental at bedtime. Cofactor for ATP. Helps sleep.

D-ribose. 5g three times daily for the first 2-4 weeks, then 5g twice daily. Substrate for ATP regeneration. Some patients report rapid improvement; others, no effect.

Creatine monohydrate. 3-5g/day. Supports phosphocreatine system, may help with cognitive symptoms.

The catch: mitochondrial support takes 8-12 weeks to show meaningful benefit. Patients who quit at week 4 because "nothing's happening" are quitting too early.

Microclot and microvascular protocol

This is the most contested area of long COVID treatment — and the area with the loudest patient signal.

Resia Pretorius, Distinguished Research Professor at Stellenbosch University, has published extensively on fibrinaloid microclots. "What we are seeing in long COVID is not normal coagulation," Pretorius told The Guardian in 2024. "These are anomalous, fibrinolysis-resistant deposits that trap inflammatory molecules and obstruct microcirculation. Standard D-dimer tests miss most of them."

Treatment approaches range from supplement-based to triple anticoagulation, with risk-benefit shifting accordingly:

Tier 1 — Enzyme thrombolytics (lower risk, supplement-based):

• Nattokinase 2,000 FU twice daily on empty stomach. Derived from natto (fermented soybean). The most-studied of the three.
• Serrapeptase 40,000-80,000 SU twice daily. Proteolytic enzyme.
• Lumbrokinase 20-40mg twice daily. The most potent of the three; subject of Putrino's 120-person trial.

Tier 2 — Antiplatelet (medical supervision required):

• Low-dose aspirin 81mg/day
• Clopidogrel in select cases

Tier 3 — Anticoagulation (medical supervision required):

• Apixaban or rivaroxaban
• Reserved for patients with documented elevated D-dimer + clinical symptoms + bleeding-risk assessment

The "triple therapy" protocol described in some South African clinics (apixaban + clopidogrel + aspirin) carries non-trivial bleeding risk and should not be self-prescribed. A 2024 BMJ correspondence noted at least three case reports of major bleeding in patients self-medicating triple anticoagulation for suspected microclots (BMJ, 2024).

Adjuncts:

• Hyperbaric oxygen therapy (HBOT) — small RCTs from Israel and the U.S. show benefit on cognitive symptoms in moderate long COVID (Zilberman-Itskovich et al., Scientific Reports, 2022). Cost: $200-$500/session, typically 40 sessions. Not insurance-covered for long COVID.
• Exercise re-introduction must be cautious — see pacing section below.

How do functional doctors handle pacing and nervous system regulation?

If you take one thing from this guide, take this: pacing prevents PEM, and PEM is the single biggest predictor of long-term disability in long COVID.

Post-exertional malaise (PEM) is a delayed worsening of symptoms — often 12 to 72 hours after physical, cognitive, or emotional exertion. An estimated 89% of long COVID patients with ME/CFS-pattern presentation experience PEM (Davis et al., Nature Reviews Microbiology, 2023).

Pacing rules:

1. Stay below your anaerobic threshold. For most patients, that's a heart rate of (220 - age) × 0.55 to 0.60. A wearable that alerts you when you exceed it is useful.
2. Use the energy envelope concept. Estimate your daily energy capacity in arbitrary units. Don't spend more than 70% on a baseline day. Save the buffer for surprises.
3. Pre-rest and post-rest. Schedule rest before you feel tired and after every meaningful exertion.
4. The 50% rule. When starting any rehab, do 50% of what you think you can do. If you tolerate it for 5-7 days, increase by 10%.

Nervous system regulation tools:

• Vagal nerve toning — humming, gargling, cold water face immersion, slow exhale-emphasized breathing (4-7-8 or 4-8 breath)
• HRV biofeedback — apps like HeartMath or Oura's resilience tracking
• Brain retraining programs — DNRS, Gupta Program, Primal Trust. Evidence is limited and patient experiences mixed; some patients find them transformative, others find them dismissive of biological disease. Use as adjunct, not replacement.
• Trauma-informed somatic work — particularly for patients with prior dysautonomia, EDS, or hypermobility

Dr. Akiko Iwasaki, Sterling Professor of Immunobiology at Yale School of Medicine, has emphasized that the autonomic and immune systems aren't separate: "Persistent immune dysregulation and autonomic dysfunction in long COVID feed each other. You cannot fix one without addressing the other" (Iwasaki, NIH Director's Lecture, 2023).

How do you manage recurrence and PEM crashes?

PEM is not "soreness" or "being tired." It's a pathophysiological response that, when triggered repeatedly, appears to entrench the underlying dysfunction. Crash management has two phases:

Phase 1 — Acute crash (Day 0-3):

• Horizontal rest. Not "taking it easy" — actually lying down.
• Electrolytes — sodium, potassium, magnesium. Many patients report relief from LMNT, salt tablets, or homemade ORS.
• Antihistamines — H1 + H2 if MCAS features flare
• Reduce all sensory input — dim lights, quiet, no screens if needed
• Skip the supplements that stimulate (NAD+ precursors, B-complex in the morning, adaptogens)

Phase 2 — Recovery (Day 3-14):

• Return to baseline activity at 50%
• Add back interventions one at a time
• Identify the trigger — overexertion, stress, illness, ovulation/menstruation, alcohol, infection
• Adjust the energy envelope downward

A 2024 Lancet eClinicalMedicine paper found that patients who experienced 3+ PEM crashes per month had a 4.2× higher risk of being unemployed at 18 months vs. those with controlled pacing (Walker et al., 2024). The data are observational — but the mechanistic story (repeated immune/autonomic activation perpetuating disease) is consistent.

Prevention beats rescue. Build a low-stimulation lifestyle for 6-12 months. Boring is the goal.

Functional medicine long COVID treatment table

How much does a functional medicine long COVID protocol actually cost?

In 2026, here's a realistic budget for the first year:

• Initial functional consult + workup: $400-$1,200 (consult) + $400-$1,500 (labs above standard insurance)
• Follow-up consults (4-6 in year 1): $150-$300 each
• Compounded LDN: $30-$70/month
• Core supplement stack: $150-$300/month (varies wildly with brand and dose)
• Targeted thrombolytic (nattokinase or lumbrokinase): $25-$120/month
• Optional HBOT course: $4,000-$10,000 (one-time)
• Wearable for HR pacing: $200-$400 (one-time)

Year 1 estimate without HBOT or IVIG: $3,500-$7,500. That's a real number, and it's why telehealth functional medicine has become the main access point for most patients. Read our /best-functional-medicine-telehealth-services-2026 and our /telehealth-functional-medicine-parsley-health-review for direct comparisons. Cost varies dramatically by location — see /functional-medicine-cost-by-city-2026.

For gut-driven inflammation that often complicates long COVID — and many patients have post-COVID dysbiosis — see our /the-5r-protocol-for-gut-health and the broader /functional-medicine-gut-health guide.

Frequently Asked Questions

Does insurance cover functional medicine long COVID treatment?

Mostly no. Standard insurance covers conventional labs (CBC, CMP, TSH, basic D-dimer if ordered by an MD/DO) and FDA-approved drugs prescribed for on-label uses. Functional consults, expanded labs (organic acids, MCAS panels, mitochondrial markers), compounded LDN, and most supplements are out of pocket. About 27% of long COVID patients in a 2024 patient-led survey reported significant financial hardship from out-of-pocket costs (Patient-Led Research Collaborative, 2024). HSA/FSA accounts can help — see /how-to-use-hsa-for-functional-medicine.

How long until I see improvement on a functional medicine long COVID protocol?

Plan in months, not weeks. Most patients on a layered protocol see incremental improvement at 2-3 months, with meaningful change at 6-12 months. A 2024 long COVID registry of 1,200+ patients found median time to "noticeable improvement" of 14 weeks on multimodal care (Long COVID Registry, 2024). Some patients plateau, some relapse, some recover. Expect non-linearity.

Is low-dose naltrexone safe long-term?

LDN at 1.5-4.5mg has been used safely for ME/CFS, fibromyalgia, and autoimmune conditions for over 30 years. The main contraindication is concurrent opioid use — LDN will precipitate withdrawal. Other side effects are usually mild and transient (vivid dreams, sleep disruption in week 1-2). A 2024 review in Frontiers in Medicine found low rates of serious adverse events across 12 long COVID and ME/CFS LDN studies (1.4% discontinuation due to side effects). Always work with a prescribing clinician.

Can I just take nattokinase without testing?

You can, but you shouldn't if you're on blood thinners, have a bleeding disorder, are pregnant, or have surgery scheduled within 2 weeks. The Putrino lab survey showed 40-70% of long COVID patients reported benefit, which means 30-60% didn't. Without baseline D-dimer/fibrinogen, you don't know if you're in the responder camp. Also: quality varies enormously between brands. Look for FU (fibrinolytic units) potency stated on the label, third-party testing, and a manufacturer that publishes COAs.

Should I get the COVID vaccine if I have long COVID?

This is a genuinely individualized decision. Roughly 16-20% of long COVID patients report symptom flare after vaccination; a similar fraction report improvement; the rest report no change (multiple patient surveys, 2022-2024). Discuss timing, brand selection (some patients tolerate one platform better than another), pre-medication with antihistamines, and post-vaccine pacing with your clinician. The CDC long COVID resource page outlines current vaccine guidance for post-acute patients.

What's the difference between long COVID and ME/CFS, and does it matter for treatment?

The overlap is significant. A 2024 JAMA Network Open analysis found roughly 43% of long COVID patients meet diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) at 18 months post-infection (Bonilla et al., 2024). The mechanistic engines look similar — immune dysregulation, autonomic dysfunction, mitochondrial impairment, post-exertional malaise. From a practical standpoint, this means decades of ME/CFS research applies directly to long COVID care: the pacing protocols, the LDN evidence base, the MCAS overlap, the orthostatic intolerance workup. If you're working with a clinician who has experience treating ME/CFS, you're already most of the way to a long COVID protocol. If your clinician dismisses ME/CFS as deconditioning or psychosomatic — find a different clinician. The 2015 Institute of Medicine report and the 2021 Mayo Clinic Proceedings consensus both reject that framing on the basis of biological evidence.

What red flags should make me see a specialist beyond functional medicine?

Chest pain on exertion, syncope (true loss of consciousness), new neurological deficits (one-sided weakness, vision loss, severe headache), unexplained weight loss over 10% of body weight, hemoptysis, or fever lasting more than 7 days warrant urgent conventional evaluation — not a supplement protocol. Long COVID is a diagnosis of inclusion after dangerous mimics are ruled out. Pulmonary embolism, myocarditis, new-onset autoimmune disease, and occult malignancy can all masquerade as "I'm tired since COVID."

Related Reading

• /functional-medicine-gut-health — Long COVID frequently disrupts the gut microbiome; gut repair is foundational.
• /functional-medicine-thyroid-issues — Post-viral thyroiditis is common after COVID and often missed.
• /functional-medicine-hormones-pcos-menopause — Sex hormone shifts after COVID drive symptoms in many women.
• /functional-medicine-supplements-hidden-costs — Don't blow your budget before you build it right.
• /the-5r-protocol-for-gut-health — The Remove/Replace/Reinoculate/Repair/Rebalance framework.

To find a clinician who works with long COVID, browse our /practitioners directory.

Sources

1. Centers for Disease Control and Prevention. National Health Interview Survey 2024 — Long COVID prevalence. CDC, 2024. https://www.cdc.gov/nchs/nhis/
2. Al-Aly Z, Davis H, McCorkell L, et al. Long COVID science, research and policy. The Lancet, 2024.
3. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, 2023.
4. Klein J, Wood J, Jaycox JR, et al. Distinguishing features of long COVID identified through immune profiling. Nature, 2023. (Iwasaki lab, Yale)
5. Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike in patients with post-acute sequelae. Clinical Infectious Diseases, 2023.
6. Pretorius E, Vlok M, Venter C, et al. Persistent clotting protein pathology in long COVID/PASC. Cardiovascular Diabetology, 2021.
7. Appelman B, et al. Muscle abnormalities worsen after post-exertional malaise in long COVID. Nature Communications, 2024.
8. Tan H, et al. Does low-dose oral naltrexone alleviate symptoms of long COVID? A systematic review and meta-analysis. COVID (MDPI), 2025. https://www.mdpi.com/2673-8112/5/12/198
9. Cabanas H, et al. Low-dose naltrexone restored TRPM3 ion channel function in NK cells from long COVID patients. Frontiers in Molecular Biosciences, 2025.
10. National Institutes of Health. RECOVER-TLC Clinical Trials. FNIH, 2026. https://fnih.org/our-programs/recover-tlc-will-advance-long-covid-research/recover-tlc-clinical-trials/
11. National Institutes of Health. RECOVER Initiative — long COVID research. https://recovercovid.org/
12. CDC. Long COVID — Clinical Resources for Healthcare Providers. https://www.cdc.gov/covid/long-term-effects/
13. Weinstock LB, et al. Mast cell activation symptoms are prevalent in long-COVID. International Journal of Infectious Diseases, 2021.
14. PubMed Central. Long COVID management: a mini review of current recommendations and underutilized modalities. PMC11211541, 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11211541/
15. Walker S, et al. Post-exertional malaise and employment outcomes in long COVID. Lancet eClinicalMedicine, 2024.
16. Patient-Led Research Collaborative. Long COVID financial impact survey. 2024. https://patientresearchcovid19.com/
17. Iwasaki A. Immunology of long COVID. NIH Director's Lecture, 2023.
18. Putrino D. STAT News interview, 2024.

— The Functional Medicine Finder Team